BluePath Solutions

Join us for our next session in the #BluePath series of #webinars! We are excited to announce the next topic of our webinar series – an overview of key trends in the #MedicarePartB market for physician-administered drugs in the US. The Medicare Part B market for physician-administered drugs represents a dynamic and growing segment of the overall #biopharmaceutical market in the US.?For manufacturers with commercially available and/or pipeline asset Part B drugs, this market is characterized as one undergoing rapid change due to policy changes associated with the #IRA as well as the emergence of #biosimilars.? ? In this webinar we will explore topics such as Part B market size and structure, site of care, payment dynamics, and net pricing trends driven by competitive forces.?For years, the Part B drug market has been generally viewed as one in which price competition is limited and the price concessions being made by manufacturers are opaque in nature.?Using new net pricing technology developed by BluePath, we will share select examples of how Part B net pricing dynamics are evolving in a new era shaped by the introduction of biosimilars and intensified brand competition. Matthew Gitlin, Founder and Managing Director at BluePath Solutions, and Brian Duffant, Partner at BluePath Solutions, will lead an informative overview of the latest developments and related implications for biopharmaceutical manufacturers with physician-administered drug assets. Participate in our webinar to learn more! Register for free today to secure your spot! We look forward to seeing you there. Registration Link: https://lnkd.in/gaXzJpW9?

Physician-administered drugs represent a large and growing market in Medicare Part B.?The Medicare Payment Advisory Commission (MedPAC), an independent congressional agency established to advise the US Congress on Medicare issues, has issued a series of proposed Part B payment policy reforms.?While no current legislation is pending, these MedPAC recommendations represent potential policy changes which should be monitored by manufacturers of physician-administered drugs.?For additional information on the proposed policies, please click on the link below: https://lnkd.in/g6H-PcwD

We’re just a few weeks away from our first #webinar! Join us as we focus on the Inflation Reduction Act (IRA) and its impact on the #Medicare market. What to Expect: ? Insights on key changes in the #IRA affecting biopharmaceutical brands? ? Overview of drug price negotiation, Part D benefit redesign, and more? ? Expert analysis from Brian Duffant, Partner at BluePath Solutions? Register for free here: https://lnkd.in/gHPqGnNV Don’t miss this valuable opportunity to stay informed. We hope to see you there!

We're #hiring for a Payer Value Marketing Strategic Lead on our Value Marketing & Communications Team. Apply today or share this post with your network.

Join Us for Our 1st Webinar! We are thrilled to announce the first topic of our webinar series – an overview on #IRA dynamics. The Inflation Reduction Act (IRA) will bring substantial changes to the #Medicare market in the US.? For biopharmaceutical brands with utilization in the Medicare market, these core changes include drug price negotiation for select brands, Part D benefit redesign, and the introduction of drug inflation rebate penalties for brand drugs exceeding certain price increase thresholds. ? While changes from price negotiation do not take effect until 2026, several new programs such as the Manufacturer Discount Program and Medicare Prescription Payment Plan will become effective as of January 1, 2025, which suggests manufacturers should be planning for the potential impact of these new programs.? Understanding the key changes in the IRA and related uncertainty they bring to the market is important to help manufacturers inform brand reimbursement and #marketaccess plans. Brian Duffant, Partner at BluePath Solutions, will lead an informative overview of the latest IRA developments and related implications for biopharmaceutical manufacturers. Participate in our webinar to learn more! Register for free today to secure your spot! We look forward to seeing you there. Registration Link: https://lnkd.in/gHPqGnNV

We’re Excited to Announce the Launch of Our New Webinar Series! Join us as we dive into a world of knowledge and insights with our upcoming #webinars, designed to empower and inspire you with valuable understandings of the latest advancements and trends in the #biopharmaceutical space. Whether you’re an industry professional, researcher, or simply interested in the field, this series is for you! What to Expect: ? Expert Speakers: Learn from industry leaders and subject matter experts. ? Interactive Sessions: Participate in live Q&A sessions and polls to share your thoughts. ? Engaging Topics: Explore a wide range of subjects. ? Convenient Access: Participate from anywhere. Don’t miss out on this exciting opportunity. Stay tuned for more updates on #BluePath Solutions’ 1st webinar coming soon!?

The FDA has proposed a change in biosimilar switching study requirements.?Should the proposed changes be adopted, they could result in a material change to biosimilar adoption rates and related erosion rates for the relevant reference brand.?For additional details on the proposed changes and implications, please click on the link below. https://lnkd.in/gHnSFvan

Research on positive symptoms of schizophrenia is well documented; however, cognitive, and negative symptoms of the illness have no approved therapies. Attaining clinical stability is of paramount importance. Nevertheless, outcomes beyond those assessed in clinical trials are also relevant. To better gauge the economic impact of cognitive impairment and negative symptoms of schizophrenia on outcomes pertinent to U.S. stakeholders, our colleagues recently published a targeted literature review. Utilizing EMBASE and Pubmed, spanning a decade, they identified eight studies with data on outcomes of potential interest. Key results suggest that patients with schizophrenia and moderate/severe cognitive impairment had twice as many relapse-related hospitalizations and emergency room visits compared to patients with no/mild cognitive impairment. Furthermore, there was almost a one-and-a-half increase in outpatient visits and inpatient admissions for patients with negative symptoms compared to patients without negative symptoms. This review highlights the need for research on interventions addressing cognitive impairment and negative symptoms of schizophrenia. ? Christoph U. Correll, Pin Xiang, Kaushik Sarikonda, Nikhil Bhagvandas, and Matthew Gitlin. The Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia: A Targeted Literature Review With a Focus on Outcomes Relevant to Health Care Decision-Makers in the United States, J Clin Psychiatry. August 21, 2024. https://lnkd.in/gVT_DChX.

CMS recently published the maximum fair price for each of the ten brand drugs selected for negotiation in the first round of Medicare Part D price negotiations. Maximum fair price discounts average 63% across the initial ten brands selected and these rates appear to be higher than average therapeutic class rates previously negotiated between manufacturers and Part D plan sponsors. For additional details and implications of the coming price changes in 2026, please click on the link below for BluePath’s take on a milestone event in US drug pricing. https://lnkd.in/gyfbnXy4

UPDATE: CY 2025 Final Rule for the Medicare Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems CMS recently released proposed Contract Year 2025 Medicare payment rates for hospital outpatient and ambulatory surgical center sites of care.?The 60-day comment period is now open, and interested parties have until September 9 to comment on the proposed payment rates. For additional information on the proposed payment rates and related new policies, please click on the link below: https://lnkd.in/g3DnRDXQ